MX2021001841A - Anticuerpos anti-gdf15, composiciones y metodos de uso. - Google Patents

Anticuerpos anti-gdf15, composiciones y metodos de uso.

Info

Publication number
MX2021001841A
MX2021001841A MX2021001841A MX2021001841A MX2021001841A MX 2021001841 A MX2021001841 A MX 2021001841A MX 2021001841 A MX2021001841 A MX 2021001841A MX 2021001841 A MX2021001841 A MX 2021001841A MX 2021001841 A MX2021001841 A MX 2021001841A
Authority
MX
Mexico
Prior art keywords
methods
compositions
antibodies
gdf15 antibodies
gdf15
Prior art date
Application number
MX2021001841A
Other languages
English (en)
Inventor
Tao He
James R Apgar
Matthew Allister Lambert
Kevin Charles Beaumont
Danna M Breen
Jeffrey Raymond Chabot
Ksenya Shchors
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2021001841A publication Critical patent/MX2021001841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención proporciona anticuerpos y fragmentos de unión al antígeno de los mismos que se unen específicamente a GDF15, así como métodos y usos de los anticuerpos.
MX2021001841A 2018-08-20 2019-08-15 Anticuerpos anti-gdf15, composiciones y metodos de uso. MX2021001841A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862765289P 2018-08-20 2018-08-20
US201862750479P 2018-10-25 2018-10-25
US201862750393P 2018-10-25 2018-10-25
US201962881064P 2019-07-31 2019-07-31
PCT/IB2019/056932 WO2020039321A2 (en) 2018-08-20 2019-08-15 Anti-gdf15 antibodies, compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2021001841A true MX2021001841A (es) 2021-05-13

Family

ID=69232873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001841A MX2021001841A (es) 2018-08-20 2019-08-15 Anticuerpos anti-gdf15, composiciones y metodos de uso.

Country Status (16)

Country Link
US (2) US11566066B2 (es)
EP (1) EP3841121A2 (es)
JP (2) JP7155403B2 (es)
KR (1) KR20210049840A (es)
CN (1) CN112912395A (es)
AU (1) AU2019323790A1 (es)
BR (1) BR112021003173A2 (es)
CA (1) CA3109905A1 (es)
CO (1) CO2021001893A2 (es)
IL (1) IL280963A (es)
MX (1) MX2021001841A (es)
PE (1) PE20211412A1 (es)
PH (1) PH12021550337A1 (es)
SG (1) SG11202101502YA (es)
TW (1) TWI803682B (es)
WO (1) WO2020039321A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2900263T3 (pl) 2012-09-26 2019-10-31 Univ Wuerzburg J Maximilians Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (GDF-15)
SG11202101502YA (en) * 2018-08-20 2021-03-30 Pfizer Anti-gdf15 antibodies, compositions and methods of use
EP4106815A4 (en) * 2020-02-21 2024-04-24 Childrens Medical Ct Corp METHODS OF TREATING ASTHMA OR ALLERGIES
WO2021186396A2 (en) * 2020-03-18 2021-09-23 Oncotelic Inc. Tgf-beta inhibition, agents and composition therefor
CN116209436A (zh) * 2020-05-14 2023-06-02 奥古斯塔大学研究所股份有限公司 作为用于covid-19的治疗方式的大麻二酚
CA3199951A1 (en) * 2020-10-30 2022-05-05 Hideaki Hara Gdf15 modulators for use in inhibiting ocular tissue fibrosis
JP2023548430A (ja) * 2020-11-10 2023-11-16 キャタライム・ゲーエムベーハー 抗ｇｄｆ１５抗体及びがんの処置のための投薬レジメン
JP2024516320A (ja) * 2021-05-07 2024-04-12 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Ｆｃ受容体への結合が改変されたＦｃ変異体
JPWO2022255401A1 (es) * 2021-06-03 2022-12-08
IL310535A (en) * 2021-08-10 2024-03-01 Byomass Inc Anti-GDF15 antibodies, compositions and uses thereof
US20230107304A1 (en) * 2021-09-10 2023-04-06 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia
WO2023048425A1 (ko) * 2021-09-24 2023-03-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
WO2023079430A1 (en) 2021-11-02 2023-05-11 Pfizer Inc. Methods of treating mitochondrial myopathies using anti-gdf15 antibodies
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023141815A1 (zh) * 2022-01-26 2023-08-03 康源博创生物科技(北京)有限公司 抗生长分化因子15的抗体分子及其应用
WO2023217068A1 (zh) * 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
EP2783698A1 (en) 2007-08-16 2014-10-01 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PT2644698T (pt) * 2010-11-17 2018-01-31 Chugai Pharmaceutical Co Ltd Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
SG11201402603WA (en) 2011-11-28 2014-06-27 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
AR094271A1 (es) * 2012-12-21 2015-07-22 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15
EP4316596A3 (en) * 2014-03-26 2024-04-17 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
WO2015196142A1 (en) 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
HUE054670T2 (hu) 2014-09-25 2021-09-28 Aveo Pharmaceuticals Inc Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
SG11202101502YA (en) 2018-08-20 2021-03-30 Pfizer Anti-gdf15 antibodies, compositions and methods of use

Also Published As

Publication number Publication date
US11566066B2 (en) 2023-01-31
TWI803682B (zh) 2023-06-01
KR20210049840A (ko) 2021-05-06
WO2020039321A2 (en) 2020-02-27
US20220380448A1 (en) 2022-12-01
PH12021550337A1 (en) 2021-10-04
AU2019323790A1 (en) 2021-03-11
WO2020039321A3 (en) 2020-05-07
JP7155403B2 (ja) 2022-10-18
CO2021001893A2 (es) 2021-03-08
EP3841121A2 (en) 2021-06-30
SG11202101502YA (en) 2021-03-30
PE20211412A1 (es) 2021-08-02
JP2022188191A (ja) 2022-12-20
BR112021003173A2 (pt) 2021-05-11
IL280963A (en) 2021-04-29
TW202021619A (zh) 2020-06-16
CN112912395A (zh) 2021-06-04
US20200055930A1 (en) 2020-02-20
CA3109905A1 (en) 2020-02-27
JP2021526847A (ja) 2021-10-11
WO2020039321A8 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2018016364A (es) Anticuerpos anti-pd-l1.
TN2018000076A1 (en) Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
SG10201901057UA (en) Anti-pd-l1 antibodies
EA201792221A1 (ru) Антитела против сортилина и способы их применения
NZ766356A (en) Anti-pd-1 antibodies
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
NZ760841A (en) Agonist antibodies that bind human cd137 and uses thereof
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
MX2022015258A (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
PH12019502694A1 (en) Anti-trkb antibodies
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
EA201992747A1 (ru) Антитела к fam19a5 и их применение
EA202090257A1 (ru) Антитела-агонисты, которые связывают cd137 человека, и варианты их применения